Published 11/06/2009 by Nasdaq
Biogen Updates Tysabri Label To Reflect Risk With Longer Use
NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) amended the U.S. label of multiple sclerosis treatment Tysabri, sold with Elan Corp. PLC (ELN), on Friday to reflect that the risk of a rare brain infection rises with longer usage.
The changes, which were expected, note that the occurrence...
Share this
There are no more reports on this story yet.